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ABSTRACT 
A series of twenty-six carbamates derived from aminocombretastatin A-4 (AmCA-4) were 
synthesized and evaluated for their capacity to affect cell proliferation, tubulin polymerization, mitotic 
cell arrest, microtubule network organization, apoptosis and endothelial tubular structures in vitro. The 
anti-proliferative activity of the synthetic carbamates was measured on several human tumor cell lines 
(i.e. HT-29, MCF-7, HeLa, A-549, MDA-MB-231, HL-60) as well as on the endothelial cell line 
HMEC-1 and the non-tumor cell line HEK-293. The compounds showed anti-proliferative activity in 
the nanomolar range thereby exceeding by far the activity of combretastatin A-4 (CA-4) and, in some 
cases, the activity of AmCA-4. The most active compounds proved to be the carbamates bearing 
chloro, bromo or methoxy groups in the meta position of the phenyl ring. Moreover, all carbamates 
inhibited in vitro tubulin polymerization, in a similar manner to that of CA-4 and AmCA-4 by 
interacting with the colchicine binding site in tubulin. The synthetic carbamates proved as active as 
AmCA-4 in causing mitotic arrest, as assessed in A549 human lung cancer cells, and disruption of the 
microtubule cellular network. Some selected carbamates induced apoptosis at concentrations as low as 
10 nM, being more active than AmCA-4. Finally, these selected carbamates displayed a vascular 
disrupting activity on endothelial cells in a dose-dependent manner. In conclusion, our data indicate 
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that carbamates derived from aminocombretastatin A-4 represent interesting lead compounds for the 
design of vascular disrupting agents. 
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1. Introduction 
The tumor vasculature supplies oxygen and nutrients to the fast-growing tumor cells and removes 
toxic metabolites from the tumor site. However, this vascular network is highly disordered, tortuous 
and unstable due to the lack of proper regulation of the angiogenic process [1].The high density of 
abnormal intratumoral blood vessels allows cancer cells to easily gain access to the blood thus 
triggering the metastasis process. Blocking the tumor vasculature is thus an alternative approach to 
traditional radio- and chemotherapy in the fight against cancer. There are two main approaches to 
achieve this goal either by preventing new blood vessel formation (i.e. anti-angiogenic agents) or by 
directly destroying the tumor vasculature. Vascular disrupting agents (VDAs) are compounds that 
selectively damage the unstable tumor vasculature thus causing tumor ischemia and necrosis.  
One class of VDAs, that includes the well-studied colchicine and combretastatin A-4, exerts their 
action by binding to tubulin, the protein that forms the cytoskeletal microtubules. This binding destroys 
the cellular structural framework and disrupts intercellular junctions, leading to loss of morphology and 
cohesion of tumor vascular endothelial cells and to subsequent collapse of the tumor vasculature [2]. 
Combretastatin A-4 (CA-4), a natural phenolic stilbene which has been isolated from the African 
willow tree Combretum caffrum (see figure 1), is a potent anti-mitotic agent against a variety of cancer 
cells, including multi-drug resistant cancer cell lines [3]. CA-4 also acts on proliferating endothelial 
cells [4] and displays vascular disrupting action [5]. The poor water solubility of CA-4 has prevented 
its use as an anticancer drug which explains the development of phosbretabulin, a water-soluble 
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prodrug of CA-4 that also shows potent antivascular and antitumor effects in a wide variety of tumor 
cell lines [6]. In the last years several VDAs, such as combretastatin A-4 phosphate (Phosbretabulin 
disodium salt), AVE8062 (Ombrabulin), DMXAA (Vadimezan), NPI-2358 (Plinabulin) and MPC-
6827 have entered phase 2-3 trials (see figure 1) [7]. 
 
Figure 1. 
The poor water solubility of CA-4 has prevented its use as an anticancer drug which explains the 
development of aminocombretastatin (AmCA-4), a non-natural combretastatin, and Ombrabuline, a 
serine-derivative from AmC4-4 (see figure 2). These compounds also show strong cytotoxicity, 
inhibition of tubulin polymerization and antivascular activity [8].  
Several drugs exhibit a carbamate group in their structures as in rivastigmine (used for the treatment 
of dementia), retigabine (prescribed for the treatment of epilepsies), morizicine (used for the treatment 
of arrhythmias), zafirlukast (used for the treatment of asthma), and as in antiretroviral drugs used for 
the treatment of HIV/AIDS, like efavirenz, ritonavir, darunavir, fosamprenavir, atazanavir and 
cobicistat. Carbamate functionality confers chemical and proteolytic stability and a great capacity to 
pass through cell membranes which explains the increasing use of carbamates in medicinal chemistry 
[9]. The delocalization of nonbonded electrons of nitrogen over the carboxyl moiety causes a 
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conformational rigidity. In addition, the NH and the carboxyl group exhibit excellent capacities for the 
formation of hydrogen bonds. Thus, substitution on the N- and O-termini of a carbamate allows to fine-
tune the biological and pharmacokinetic properties of carbamate-bearing molecules. 
In particular, the cis-stilbene structural fragment of CA-4 can be considered as a privileged motif 
with regard to VDA activity [10]. Figure 2 depicts a compound in which aminocombretastatin A-4 and 
a functionalized phenol have been linked through the intermediacy of a carbamate group. 
 
Figure 2. 
2. Research purpose 
During the past few years we have been investigating a range of analogues of natural products for 
their potential value in anticancer therapy [11]. We have published several reports on the biological 
properties of combretastatin A-4 derivatives [12]. Therefore, on the basis of the aspects commented 
above and in continuation of our research on novel natural product analogues with potential utility in 
cancer therapy, we wanted to study whether carbamoylation of the amino group in 
aminocombretastatin A-4 improves its biological activity [13]. The synthesis of this new family of 
combretastatin-derived carbamates is described in scheme 1. The structures of the synthesized 
carbamates are indicated in figure 3. 
 
3. Synthetic work 
Aminocombretastatin was prepared by total synthesis following a published procedure [14]. For the 
synthesis of carbamates two procedures were applied. In the indicated Method a in scheme 1 
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carbamates were directly achieved upon reaction of AmCA-4 with commercially available aryl 
chloroformates in THF in the presence of pyridine [15]. The low commercial availability of aryl 
chloroformates allowed only the synthesis of three carbamates with the application of Method a 
(compounds 1, 4 and 7, see figure 3). The remaining carbamates were prepared by one-pot Method b in 
which AmCA-4 was converted into the corresponding trichloromethylcarbamate, upon reaction with 
triphosgene and Et3N, which in turn was transformed into carbamates by reaction with a range of 



















Scheme 1. Reagents and conditions: Method a: ArOCOCl, pyridine, THF, 0ºC 30 min then rt 1 h. Method b: (i) 










1 (R1, R2=H, method a , 89%)
2 (R1=2-F, R2=H, method b, 73%)
3 (R1=3-F, R2=H, method b, 33%)
4 (R1=4-F, R2=H, method a , 64%)
5 (R1=2-Cl, R2=H, method b, 35%)
6 (R1=3-Cl, R2=H, method b, 33%)
7 (R1=4-Cl, R2=H, method a , 62%)
8 (R1=2-Br, R2=H, method b, 36%)
9 (R1=3-Br, R2=H, method b, 58%)
10 (R1=4-Br, R2=H, method b, 61%)
11 (R1=2-OMe, R2=H, method b, 41%)
12 (R1=3-OMe, R2=H, method b, 91%)
13 (R1=4-OMe, R2=H, method b, 73%)
14 (R1=2-Me, R2=H, method b , 27%)
15 (R1=3-Me, R2=H, method b, 45%)
16 (R1=4-Me, , R2=H, method b, 49%)
17 (R1=2-CF3, R
2=H, method b , 65%)
18 (R1=3-CF3, R
2=H, method b, 50%)
19 (R1=4-CF3, R
2=H, method b, 75%)
20 (R1=2-Me, R2=6-Me, method b, 24%)
21 (R1=3-Me, R2=5-Me, method b, 18%)
22 (R1=2-Me, R2=3-Me, method b, 28%)
23 (R1=3-Me, R2=4-Me, method b, 27%)
24 (R1=2-Me, R2=3-Cl, method b, 55%)
25 (R1=3-Me, R2=4-Cl, method b, 31%)




Figure 3. Structure of the carbamates investigated in this study. 
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4. Biological work 
4.1. Inhibition of cell proliferation 
The ability of compounds 1-26 to inhibit cell proliferation was established by means of their IC50 
values towards the human tumor cell lines HT-29 (colon adenocarcinoma), MCF-7 (breast 
adenocarcinoma), HeLa (epithelioid cervix carcinoma), HL-60 (promyelocytic leukemia), A-549 
(pulmonary adenocarcinoma) and MDA-MB-231 (breast adenocarcinoma) as well as towards the 
endothelial cell line HMEC-1 (human microvascular endothelial cells) and the non-tumor cell line 
HEK-293 (human embryonic kidney cells). The IC50 values are presented in Table 1 (nM) along with 
IC50 values for the parent compounds CA-4 and AmCA-4 (see Supporting Information for MDA-MB-
231 cells). 
Some trends can be deduced from Table 1. Thus, the majority of the compounds show activity in the 
low nanomolar range in all cell lines except in A549, in which the activity lies in the high nanomolar 
range. In general, carbamate derivatives show better IC50 values than AmCA-4 in most of the tested 
tumor cell lines. Moreover, halo- and methoxy-phenyl carbamates substituted at position 3 of the 
phenyl ring showed higher antiproliferative activity than their regioisomeric counterparts, particularly 
in MCF-7, HT-29, HeLa and A549 cell lines. As regards therapeutic range, compounds 4, 5, 6, 9, 10 
and 19 show greater selectivity since the most of their IC50 values in MCF-7, HT-29, HeLa and HL-60 
tumor cell lines are 2- to 11-fold lower than their IC50 values in the non-tumor cell line HEK-293. As 
regards endothelial cells (HMEC-1), compounds 6, 10, 12, 25 and 26 show better antiproliferative 
activity than AmCA-4 (see table 1). These latter compounds are mainly substituted in meta and para 
positions with halogen atoms or their bioisosters. 
Table 1. IC50 values (nM) for CA-4, AmCA-4 and derivatives 1-26.a  
Comp. HT-29 MCF-7 HeLa A549 HL-60 HMEC-1 HEK-293 
CA-4 4200 ± 500 1000 ± 200 2100 ± 600 130 ± 20  4000 ± 1000 3400 ± 400 25000 ± 300 
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AmCA-4 22.0 ± 0.7 8.0 ± 0.9 2.6 ± 0.5 117 ± 7 4.5 ± 0.9 12 ± 6 7.1 ± 1.0 
1 2.9 ± 0.5 9.8 ± 0.1 4.8 ± 0.2 77 ± 12 4 ± 2 12 ± 5 3.3 ± 0.2 
2 110 ± 30 62 ± 2 17 ± 2 320 ± 190 4 ± 2 180 ± 20 65 ± 4 
3 10.6 ± 0.5 7.0 ± 0.6 2.7 ± 1.3 150 ± 40 60 ± 20 20 ± 2 13.2 ± 0.2 
4 60 ± 20 95.4 ± 1.3 60 ± 20 400 ± 200 50 ± 30 65 ± 13 185 ± 2 
5 17.8 ± 0.7 10.1 ± 0.8 5 ± 2 130 ± 40 3.7 ± 0.7 50 ± 30 41 ± 2 
6 9.2 ± 1.3 4.4 ± 0.6 4.79 ± 0.03 100 ± 20 13.5 ± 1.6 9 ± 6 14.5 ± 0.4 
7 31 ± 14 82 ± 13 24 ± 3 800 ± 200 770 ± 170 76 ± 13 142 ± 9 
8 7.5 ± 0.6 18.9 ± 0.9 2.6±1.0 180 ± 50 3 ± 2 22 ± 7 8 ± 5 
9 11.3 ± 0.7 5.9 ± 0.3 2.6±0.5 160 ± 30 5.6 ± 0.6 12 ± 4 16 ± 2 
10 3.5 ± 0.2 0.75 ± 0.05 1.2±0.2 150 ± 30 5 ± 3 7 ± 4 19 ± 7 
11 290 ± 100 230 ± 180 348 ± 13 3000 ± 1100 350 ± 190 400 ± 15 160 ± 40 
12 4.8 ± 0.5 7.18 ± 0.07 3.4 ± 0.4 160 ± 40 4.9 ± 0.5 5 ± 2 8.1 ± 0.2 
13 350 ± 20 230 ± 30 200 ± 40 550 ± 120 50 ± 6 120 ± 50 130 ± 40 
14 160 ± 70 380 ± 50 50 ± 30 460 ± 110 222 ± 7 55 ± 6 60 ± 20 
15 46 ± 3 25 ± 9 23 ± 13 390 ± 180 67 ± 2 50 ± 20 40 ± 20 
16 270 ± 80 200 ± 60 370 ± 160 1500 ± 300 52 ± 2 160 ± 40 144 ± 10 
17 16 ± 7 44 ± 2 15 ± 4 110 ± 40 6.7 ± 0.6 19 ± 5 4.1 ± 1.0 
18 13 ± 3 56 ± 9 40 ± 8 130 ± 60 4 ± 2 16 ± 5 42.2 ± 0.9 
19 27.6 ± 0.6 9.2 ± 0.3 21 ± 8 270 ± 70 40 ± 30 30 ± 8 57 ± 22 
20 600 ± 200 440 ± 14 320 ± 120 3900 ± 1200 470 ± 70 380 ± 140 490 ± 80 
21 260 ± 140 210 ± 20 130 ± 16 1540 ± 80 620 ± 90 180 ± 7 150 ± 80 
22 175 ± 4 16 ± 3 40 ± 20 900 ± 200 59 ± 13 140 ± 40 80 ± 30 
23 130 ± 20 170 ± 30 21 ± 6 1300 ± 600 69 ± 11 130 ± 50 97 ± 9 
24 47 ± 2 39 ± 3 23 ± 12 140 ± 30 70 ± 30 20 ± 2 14 ± 2 
25 11.4 ± 0.3 8.1 ± 0.9 3.3 ± 0.5 140 ± 30 0.4 ± 0.2 7 ± 1 8.4 ± 0.6 
26 23 ± 2 6.1 ± 0.8 3.7 ± 0.3 90 ± 20 1.8 ± 0.6 6 ± 2 7.0 ± 0.8 
aIC50 values are expressed as the compound concentration (nM) that inhibits the cell growth by 50%. Data are the 
average (±SD) of three experiments.  
4.2. Tubulin polymerization process 
In order to evaluate the effects of the synthetic derivatives on tubulin self-assembly, the critical 
concentration (CrC) was determined. All compounds were tested at a concentration of 27.5 μM in 
glycerol-assembling buffer (GAB) and GTP to which tubulin was added at a concentration of 25 μM. 
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The results achieved with the carbamates are shown in table 2 and are compared with those attained in 
the absence of any ligand (control) and in the presence of CA-4 or AmCA-4. 
Table 2. Critical Concentration (CrC) for the assembly of purified tubulin in GAB in the presence of 
CA-4, AmCA-4 or the carbamates. 
Compound CrC (µM) Compound CrC (µM) 
Control   8 ± 1 13 23 ± 2 
CA-4 22 ± 1 14 22 ± 3 
AmCA-4 23 ± 2 15 20 ± 3 
1 20 ± 2 16 25 ± 2 
2 18 ± 3 17 23 ± 2 
3 24 ± 4 18 14 ± 2 
4 22 ± 2 19 20 ± 3 
5 21 ± 3 20 17 ± 3 
6 23 ± 2 21 24 ± 2 
7 24 ± 2 22 25 ± 2 
8 22 ± 2 23 21 ± 2 
9 25 ± 3 24 23 ± 1 
10 23 ± 2 25 24 ± 3 
11 16 ± 1 26 24 ± 3 
12 20 ± 2   
Data are the average (±SD) of three experiments. 
All carbamates increased the CrC value relative to the value measured in the control (absence of 
ligand) with CrC values similar to those achieved in the presence of CA-4 or AmCA-4. 
Figure 4 shows the effects of some selected ligands on the in vitro tubulin polymerization process 
studied by turbidimetry time-course measurements at 350 nm and at 37ºC. In order to compare, 
paclitaxel, a microtubule stabilizer, was also evaluated. 
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Figure 4. Effects of CA-4, AmCA-4 and carbamates on the in vitro tubulin polymerization. 
 
4.3. Tubulin interaction at the colchicine binding site 
In order to check whether the carbamates interact with tubulin in the colchicine-binding site the EBI 
assay was undertaken. This method is based on the property of N,N’-ethylene-bis(iodoacetamide) 
(EBI), a homobifunctional thioalkylating agent, to crosslink the Cys-239 and the Cys-354 residues 
present in the colchicine-binding site of β-tubulin. The covalent binding of EBI to β-tubulin forms an 
adduct that is easily detected by Western Blot as a second immunoreacting band of β-tubulin that 
migrates faster than the native β-tubulin band. As a consequence, treatment of the cells with a 
compound that binds to this colchicine-binding site will impair the binding of EBI, resulting in the 
absence of the second band [17]. The carbamates tested were selected according to their IC50 value in 
MDA-MB-231 (see Supporting Information), thus the three compounds with the lowest IC50 values 
(10, 12 and 25) and two additional carbamates with higher IC50 values (11 and 13) were chosen for this 
study. With this selection we intended to ascertain if there was any correlation between the 
antiproliferative activity of the compounds and their capacity to interact with tubulin. The results of this 
assay are depicted in figure 5. 
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Figure 5. Effects of colchicine and carbamates at the colchicine-binding site of tubulin. 
 
As shown in figure 5, there is a dose-response effect for all compounds tested. Concretely, 
compounds 10, 12 and 25 were able to inhibit the formation of EBI adduct at 3 µM, showing a 
behaviour similar to that of colchicine at this concentration. However, compounds 11 and 13 were less 
effective since they required higher concentrations (100 µM for 11 and 10 µM for 13) to avoid being 
displaced by EBI from tubulin. Thus, this experiment demonstrates that the compounds bind tubulin at 
the colchicine-binding site and that their antiproliferative capacity correlates with tubulin binding. 
4.4. Mitotic arrest and inhibition of interphase microtubules of cultured 
The effects of carbamates on cell cycle distribution were evaluated in A549 cells. Thus, cells were 
incubated for 20 h in the presence of CA-4, AmCA-4 and compounds 1-26 and then, DNA content was 
measured by flow cytometry (see experimental section). All the carbamates extensively arrested cells in 





Table 3. Cell cycle distribution (%). 
Comp. Conc (nM) SubG0 G0/G1 S G2/M 
Control - 6.6 ± 0.1 66 ± 1 16 ± 1 11 ± 1  
CA-4 50 15 ± 1 21 ± 2 22 ± 1 43 ± 1 
AmCA-4 60 14 ± 1 21 ± 1 24 ± 1 41 ± 2 
1 40 20 ± 3 21 ± 1 15 ± 1 44 ± 3 
2 160 17 ± 1 31 ± 3 13 ± 1 39 ± 2 
3 75 19 ± 1 29 ± 1 10 ± 1 43 ± 2 
4 200  21 ± 1 26 ± 5 19 ± 1 34 ± 1 
5 65 16 ± 1 29 ± 2 12 ± 2 43 ± 3 
6 50 16 ± 2 30 ± 1 10 ± 1 44 ± 2 
7 400 20 ± 1 21 ± 1 18 ± 1 41 ± 1 
8 90 17 ± 2 29 ± 1 10 ± 1 44 ± 3 
9 80 17 ± 3 30 ± 1 12 ± 1 39 ± 1 
10 75 19 ± 1 32 ± 3 17 ± 1 33 ± 1 
11 1500 17 ± 1 29 ± 4 12 ± 3 43 ± 1 
12 80 17 ± 1 31 ± 1 16 ± 2 36 ± 3 
13 275 14 ± 1 25 ± 1 14 ± 1 46 ± 2 
14 230 16 ± 1 31 ± 2 13 ± 2 40 ± 1 
15 200 22 ± 3 26 ± 2 16 ± 3 36 ± 1 
16 750 27 ± 5 24 ± 1 16 ± 2 32 ± 3 
17 55 20 ± 2 21 ± 2 15 ± 1 44 ± 5 
18 65 16 ± 3 28 ± 1 15 ± 1 41 ± 1 
19 135 26 ± 1 22 ± 1 14 ± 1 39 ± 2 
20 2000 23 ± 2 25 ± 2 17 ± 1 35 ± 1 
21 750 22 ± 3 24 ± 3 16 ± 1 38 ± 1 
22 450 12 ± 1 24 ± 1 22 ± 3 42 ± 2 
23 650 17 ± 1 24 ± 1 19 ± 1 41 ± 1 
24 70 20 ± 1 24 ± 1 18 ± 2 39 ± 1 
25 70 18 ± 1 24 ± 1 22 ± 9 36 ± 8 
26 45 29 ± 4 21 ± 1 14 ± 1 36 ± 3 




Next, we studied the effects of compounds 1-26 on the microtubule cytoskeleton. Therefore, A549 
cells were incubated for 16 h in the presence of AmCA-4 and compounds 1-26 at concentrations twice 
their IC50 value. Figure 6 depicts some selected results. It can be appreciated that in the presence of 
AmCA-4 and carbamates, tubulin appears agregated and nuclei are compressed and fragmented, which 
is characteristic of cells that have been disturbed during their division process. 
 
Figure 6. Effects of AmCA-4 and some selected carbamates on the microtubule network. A549 cells 
were treated for 16 hours and processed for immunofluorescence microscopy: (A) DMSO, (B) 230 nM 
AmCA-4, (C) 150 nM compound 1, (D) 300 nM compound 3, (E) 260 nM compound 5, (F) 200 nM 
compound 6, (G) 220 nM compound 17 and (H) 260 nM compound 18. 
 
4.5. Induction of apoptosis 
Cell cycle distribution (Table 3) clearly shows that the percentage of subG0 cells is increased in 
cells treated with CA-4, AmCA-4 and carbamates. This exhibition of a sub-diploid DNA content, 
together with the high percentage of cells arrested in mitotic phase, could be characteristic of apoptosis. 
Consequently, induction of apoptosis was studied by measuring the translocation of phosphatidylserine 
from the cytoplasmic to the extracellular side of the plasma membrane. Thus, A549 cells were 
incubated for 20 h in the presence of AmCA-4 and some representative carbamates, after which 
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annexin content was measured by flow cytometry. Carbamates which displayed the best 
antiproliferative activity were selected for this assay. 
From figure 7 it can be concluded that carbamates induce apoptosis at both concentrations tested. 
With exception of compound 26, all of them are more active than AmCA-4 at 100 nM. Moreover, 
compounds 9 and 12 show a similar effect to AmCA-4 at 10 nM. 
 
Figure 7. Apoptotic effect of AmCA-4 and carbamates. Data are the average (±SD) of three 
experiments. 
 
4.6. Tube destruction 
Vascular-disrupting agents do not only affect tumor cells but also endothelial cells. Thus, the 
capacity of synthetic carbamates to destroy a preexisting vasculature network formed by endothelial 
cells was evaluated. Therefore, cells were seeded on top of Matrigel, which induces the formation of a 
network of endothelial tubes. Then, the cultures were treated with different concentrations of AmCA-4 
and carbamates and pictures were taken 4 h later in order to evaluate the tube destruction effect. 
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Carbamates with the best antiproliferative activity in HMEC-1 cells (compounds 10, 12 and 25) were 
selected for this assay. Additionally, two less active carbamates (11 and 13) were tested in order to 
establish a correlation between antiproliferative capacity and tube destruction. As shown in figure 8, all 
compounds tested displayed a vascular disrupting activity in a dose-dependent manner. Concretely, 
compounds 10, 12 and 25 exhibited this property at concentrations higher than 3 nM, improving the 
effect manifested by AmCA-4 and being about 10-fold more active than 13 and 100-fold more active 
than 11. Therefore, the higher the antiproliferative activity, the greater the capacity for tube destruction 
cycle distribution. 
 
Figure 8. Tube destruction effect of selected carbamates. All the compounds were tested at 3 µM, 1 
µM, 300 nM, 30 nM, 10 nM and 3 nM. 
 
The images obtained for carbamate 25 are shown in figure 9. This compound was able to totally 
destroy the vascular network at 100 nM, whereas in the presence of 100 nM of AmCA-4 or compounds 
10 and 12, part of the vascular network remained intact. 
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Figure 9. Effect of carbamate 25 on the tubular network. (A) 3 nM, (B) 10 nM, (C) 30 nM, (D) 100 
nM. 
 
4. Summary and conclusions 
The effect of introduction of a carbamate group in the aminocombretastatin structure was studied. 
As shown in table 1, carbamate derivatives offer IC50 values in the nanomolar range, improving by far 
the activity of CA-4 and, in some cases, the activity of AmCA-4. For instance, derivatives 6 (m-Cl), 9 
(m-Br), 10 (p-Br), 12 (m-OMe) exceeded the activity of AmCA-4 in HT-29, MCF-7 and HMEC-1 cell 
lines and also offered a good selectivity over non-tumor cell lines. From the structures of these 
compounds it can be concluded that the most active carbamates are the ones bearing chloro, bromo or 
methoxy groups in the meta position of the phenyl ring.  
In addition, all the carbamates proved as potent as CA-4 and AmCA-4 in inhibiting in vitro tubulin 
polymerization. We also demonstrated that carbamates interact with tubulin at the colchicine-binding 
site and that the compounds with higher antiproliferative activity (compounds 10 (p-Br), 12 (m-OMe) 
and 25 (m-Me-p-Cl) also show greater tubulin binding capacity. From cell cycle analysis and 
immunofluorescence studies it can be deduced that carbamates cause a mitotic arrest in A549 cells 
causing nuclei fragmentation and tubulin aggregation. Moreover, the carbamates induced apoptosis in a 
dose-dependent manner, with more than 90% of apoptotic cells at 100 nM. Compounds 9 (m-Br) and 
12 (m-OMe) proved as active as AmCA-4 even at a concentration of 10 nM. 
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Finally, some selected carbamates displayed a vascular disrupting activity of endothelial cells in a 
dose-dependent manner which correlated with their antiproliferative activity. Thus, highly anti-
proliferative carbamates 10 (p-Br), 12 (m-OMe) and 25 (m-Me-p-Cl) were able to disrupt tubular 
network at concentrations higher than 3 nM, improving the effect shown by AmCA-4. 
5. Experimental 
5.1. Chemistry 
5.1.1. General procedures 
NMR spectra were measured at 25°C. The signals of the deuterated solvent (CDCl3) were taken as 
the reference. Multiplicity assignments of 13C signals were made by means of the DEPT pulse 
sequence. Complete signal assignments in 1H and 13C NMR spectra were made with the aid of 2D 
homo- and heteronuclear pulse sequences (COSY, HSQC, HMBC). High resolution mass spectra were 
run by the electrospray mode (ESMS). IR data were measured with oily films on NaCl plates (oils) and 
are given only for relevant functional groups (C=O, NH). Experiments which required an inert 
atmosphere were carried out under dry N2 in flame-dried glassware. Commercially available reagents 
were used as received. 
5.1.2. Experimental procedure for the synthesis of carbamates by method a.  
A solution of AmCA-4 (0.7 mmol) in THF (5 mL/mmol) was cooled at 0ºC and anhydrous pyridine 
(1.7 mmol) and the corresponding phenyl chloroformate (1.0 mmol) were added under inert 
atmosphere. The resulting mixture was stirred in the dark for 20 min at 0ºC and for 1 h at rt. After this 
time, H2O (3.4 mL) and HCl 1M (1.7 mL) were added to the reaction mixture, which was then 
extracted with CH2Cl2 (3 x 20 mL). The organic layer was washed with brine, and then dried on 
anhydrous Na2SO4. Removal of volatiles under reduced pressure afforded an oily residue which was 
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subjected to column chromatography on silica-gel (Hexanes-EtOAc mixtures as eluant) obtaining the 
desired products with the yields indicated below. 
Phenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (1): off-white solid, m. p. 124-
126ºC; 1H NMR (500 MHz, CDCl3) δ 8.11 (br s, 1H), 7.52 (br s, 1H, NH), 7.39 (t, J ~ 7.5 Hz, 2H), 
7.24 (t, J ~ 7.5 Hz, 1H), 7.19 (d, ~ 7.5 Hz, 2H), 7.00 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 
(s, 2H), 6.51 (d, J = 12 Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H); 13C 
NMR (125 MHz, CDCl3) δ (C) 152.9 (x 2), 151.3, 150.6, 146.9, 137.2, 132.7, 130.3, 126.9, (CH) 
129.5, 129.3 (x 2), 129.2, 125.5, 123.9, 121.6 (x 2), 119.3, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 
55.8; IR νmax (cm-1) 3415 (N−H), 1750 (C=O); HR ESMS m/z 458.1588 [M+Na]+. Calc. for 
C25H25NNaO6, 458.1580. 
4-Fluorophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (4): yellowish solid, m. 
p. 138-142ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.50 (s, 1H), 7.14 (dd, J = 9, 4.5 Hz, 2H), 
7.07 (t, J ∼ 9 Hz, 2H), 7.01 (dd, J = 8.5, 2 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.50 (d, J = 
12 Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.90 (s, 3H), 3.82 (s, 3H), 3.70 (s, 6H); 13C NMR (125 MHz, 
CDCl3) δ (C) 160.1 (center point of doublet with 1JC−F ∼ 242 Hz), 152.9 (x 2), 146.9, 146.5, 146.4, 
137.2, 132.7, 130.3, 126.7, (CH) 129.5, 129.3, 124.1, 123.1 (x 2, doublet with 3JC−F ∼ 7.5 Hz), 119.3*, 
115.9 (x 2, doublet with 2JC−F ∼ 23 Hz), 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8 (starred signal 
is low and broad); IR νmax (cm-1) 3416 (N−H), 1747 (C=O); HR ESMS m/z 476.1484 [M+Na]+. Calc. 
for C25H24FNNaO6, 476.1485. 
4-Chlorophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (7): off-white solid, m. 
p. 138-140ºC; 1H NMR (500 MHz, CDCl3) δ 8.06 (br s, 1H), 7.50 (br s, 1H, NH), 7.35 (apparent d, J = 
8.8 Hz, 2H), 7.13 (apparent d, J = 8.8 Hz, 2H), 7.01 (dd, J = 8.5, 2.5 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 
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6.51 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.46 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ (C) 152.8 (x 2), 150.9, 149.1, 146.9, 137.2, 132.6, 130.8, 130.3, 126.6, 
(CH) 129.4, 129.3 (x 2), 124.1, 122.9 (x 2), 119.3*, 109.7, 106.1 (x 2), (CH3) 60.7, 55.8, 55.8 (x 2) 
(starred signal is low and broad); IR νmax (cm-1) 3414 (N-H), 1749 (C=O); HR ESMS m/z 492.1189 
[M+Na]+. Calc. for C25H2435ClNNaO6, 492.1190. 
5.1.3. Experimental procedure for the synthesis of carbamates by method b.  
A solution of AmCA-4 (0.14 mmol) in THF (4 mL/mmol) was added to a solution of triphosgene 
(0.3 mmol) in THF (0.7 ml/mmol). The resulting mixture was stirred in the dark for 10 min at rt. Then 
Et3N (4.3 mmol) was slowly added and the resulting residue was resuspended in THF (0.8 mL). The 
corresponding phenol (0.8 mmol) was added to the mixture which was stirred in the dark for 1 h at 
45ºC. After this time, volatiles were removed under reduced pressure and the remaining residue was 
dissolved in acetone. The precipitated which remained without dissolving was discarded by simple 
filtration, and then the filtrate was concentrated under reduced pressure to give an oily residue which 
was subjected to column chromatography on silica-gel (Hexanes-EtOAc mixtures as eluant) affording 
the desired products with the yields indicated below. 
2-Fluorophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (2): yellowish solid, m. 
p. 138-142ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.60 (s, 1H), 7.30-7.15 (br m, 4H), 7.00 (dd, 
J = 8.5, 2 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.45 (d, J = 12 Hz, 
1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.70 (s, 6H); 13C NMR (125 MHz, CDCl3) δ (C) 154.6 (center point of 
doublet with 1JC−F ∼ 248 Hz), 152.9 (x 2), 150.2*, 146.9, 138.0 (doublet with 2JC−F ∼ 11.5 Hz), 137.2, 
132.7, 130.3, 126.6, (CH) 129.5, 129.3, 126.8 (doublet with 3JC−F ∼ 7.5 Hz), 124.3 (doublet with 3JC−F ∼ 
3.8 Hz), 124.2, 124.1, 119.2*, 116.6 (doublet with 2JC−F ∼ 18.5 Hz), 109.7, 106.1 (x 2), (CH3) 60.8, 
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55.9 (x 2), 55.8 (starred signals are low and broad); IR νmax (cm-1) 3416 (N−H), 1753 (C=O); HR 
ESMS m/z 476.1484 [M+Na]+. Calc. for C25H24FNNaO6, 476.1485. 
3-Fluorophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (3): off-white solid, m. 
p. 127-130ºC; 1H NMR (500 MHz, CDCl3) δ 8.07 (br s, 1H), 7.50 (br s, 1H, NH), 7.34 (apparent q, J ~ 
7.7 Hz, 1H), 7.02 (dd, J = 8.5, 1.5 Hz, 1H), 7.00-6.95 (m, 3H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 
6.51 (d, J = 12 Hz, 1H), 6.46 (d, J = 12 Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H); 13C NMR (125 
MHz, CDCl3) δ (C) 162.8 (center point of doublet with 1JC−F ∼ 246 Hz), 152.9 (x 2), 151.5 (doublet 
with 3JC−F ∼ 10 Hz), 150.7*, 146.9, 137.2, 132.7, 130.4, 126.6, (CH) 130.0 (doublet with 3JC−F ∼ 8.5 
Hz), 129.5, 129.4, 124.2, 119.3*, 117.3 (doublet with 4JC−F ∼ 3 Hz), 112.5 (doublet with 2JC−F ∼ 10 Hz), 
109.7 (doublet with 2JC−F ∼ 5 Hz), 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8 (starred signals are 
low and broad); IR νmax (cm-1) 3413 (N−H), 1753 (C=O); HR ESMS m/z 476.1482 [M+Na]+. Calc. for 
C25H24FNNaO6, 476.1485. 
2-Chlorophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (5): off-white solid, m. 
p. 130-131ºC; 1H NMR (500 MHz, CDCl3) δ 8.11 (br s, 1H), 7.65 (br s, 1H, NH), 7.45 (dd, J = 7.8, 1.5 
Hz, 1H), 7.30-7.20 (m, 3H), 7.01 (dd, J = 8.5, 2 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.49 (d, 
J = 12 Hz, 1H), 6.44 (d, J = 12 Hz, 1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.70 (s, 6H); 13C NMR (125 MHz, 
CDCl3) δ (C) 152.9 (x 2), 146.9, 146.7, 137.2, 132.7, 130.3, 130.0, 127.4, 126.7, (CH) 130.3, 129.5, 
129.3, 127.6, 126.9, 124.2, 124.1, 119.2*, 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2) (starred signal is 
low and broad), 55.8; IR νmax (cm-1) 3413 (N−H), 1755 (C=O); HR ESMS m/z 492.1188 [M+Na]+. 
Calc. for C25H2435ClNNaO6, 492.1190. 
3-Chlorophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (6): off-white solid, m. 
p. 128-130ºC; 1H NMR (500 MHz, CDCl3) δ 8.07 (br s, 1H), 7.50 (br s, 1H, NH), 7.31 (t, J = 8.3 Hz, 
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1H), 7.22 (m, 2H), 7.09 (dd, J = 8.3, 1.5 Hz, 1H), 7.01 (dd, J = 8.5, 2 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 
6.52 (s, 2H), 6.51 (d, J = 12 Hz, 1H), 6.46 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ (C) 152.9 (x 2), 151.1, 150.7*, 146.9*, 137.2, 134.5, 132.7, 130.3, 
126.5, (CH) 130.0, 129.5, 129.4, 125.8, 124.2, 122.2, 119.9*, 119.3, 109.7, 106.1 (x 2), (CH3) 60.8, 
55.9 (x 2), 55.8 (starred signals are low and broad); IR νmax (cm-1) 3413 (N−H), 1754 (C=O); HR 
ESMS m/z 492.1189 [M+Na]+. Calc. for C25H2435ClNNaO6, 492.1190. 
2-Bromophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (8): off-white solid, m. 
p. 130-132ºC; 1H NMR (500 MHz, CDCl3) δ 8.11 (br s, 1H), 7.60 (br s, 1H, NH), 7.61 (dd, J = 7.8, 1.5 
Hz, 1H), 7.34 (td, J = 7.8, 1.5 Hz, 1H), 7.24 (dd, J = 7.8, 1.5 Hz, 1H), 7.13 (td, J = 7.8, 1.5 Hz, 1H), 
7.01 (dd, J = 8.5, 2 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.49 (d, J = 12 Hz, 1H), 6.45 (d, J = 
12 Hz, 1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.70 (s, 6H); 13C NMR (125 MHz, CDCl3) δ (C) 152.9 (x 2), 
150.2*, 147.9, 146.9*, 137.2, 132.7, 130.3, 126.6, 116.6, (CH) 133.2, 129.4, 129.2, 128.3, 127.2, 124.2, 
124.1, 119.2*, 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8 (starred signals are low and broad); IR 
νmax (cm-1) 3413 (N−H), 1754 (C=O); HR ESMS m/z 536.0685 [M+Na]+. Calc. for C25H2479BrNNaO6, 
536.0685. 
3-Bromophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (9): off-white solid, m. 
p. 102-105ºC; 1H NMR (500 MHz, CDCl3) δ 8.07 (br s, 1H), 7.50 (br s, 1H, NH), 7.40-7.35 (m, 2H), 
7.25 (t, J = 8 Hz, 1H), 7.14 (br d, J ~ 8 Hz, 1H), 7.01 (dd, J = 8.5, 2 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 
6.51 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.46 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H); 
13C NMR (125 MHz) δ (C) 152.9 (x 2), 151.1, 150.7*, 146.9*, 137.2, 132.7, 130.3, 126.5, 122.2, (CH) 
130.3, 129.4, 129.3, 128.7, 125.1, 124.2*, 120.4, 119.3*, 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 
55.8 (starred signals are low and broad); IR νmax (cm-1) 3412 (N−H), 1753 (C=O); HR ESMS m/z 
536.0687 [M+Na]+. Calc. for C25H2479BrNNaO6, 536.0685. 
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4-Bromophenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (10): off-white solid, 
m. p. 146-149ºC; 1H NMR (500 MHz, CDCl3) δ 8.06 (br s, 1H), 7.50 (br s, 1H, NH), 7.48 (apparent d, 
J = 8.8 Hz, 2H), 7.07 (apparent d, J = 8.8 Hz, 2H), 7.01 (dd, J = 8.5, 2.0 Hz, 1H), 6.76 (d, J = 8.5 Hz, 
1H), 6.51 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 
6H); 13C NMR (125 MHz) δ (C) 152.9 (x 2), 150.8*, 149.7, 146.9, 137.2, 132.7, 130.3, 126.6, 118.5, 
(CH) 132.3 (x 2), 129.4, 129.3, 124.1, 123.3 (x 2), 119.3*, 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 
55.8 (starred signals are low and broad); IR νmax (cm-1) 3415 (N−H), 1749 (C=O); HR ESMS m/z 
536.0690 [M+Na]+. Calc. for C25H2479BrNNaO6, 536.0685. 
2-Methoxyphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (11): off-white solid, 
m. p. 110-113ºC; 1H NMR (500 MHz, CDCl3) δ 8.13 (br s, 1H), 7.60 (br s, 1H, NH), 7.22 (td, J = 8.3, 
2 Hz, 1H), 7.14 (dd, J = 7.8, 1.5 Hz, 1H), 7.00-6.95 (br m, 3H), 6.75 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 
6.50 (d, J = 12 Hz, 1H), 6.43 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.79 (s, 3H), 3.70 (s, 6H); 
13C NMR (125 MHz) δ (C) 152.8 (x 2), 151.7, 151.0, 146.8, 139.5, 137.2, 132.7, 130.3, 127.1, (CH) 
129.6, 129.1, 126.7, 123.7, 123.3, 120.7, 119.1*, 112.4, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 3), 55.8; 
IR νmax (cm-1) 3413 (N−H), 1751 (C=O); HR ESMS m/z 488.1684 [M+Na]+. Calc. for C26H27NNaO7, 
488.1685. 
3-Methoxyphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (12): off-white solid, 
m. p. 105-108ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.50 (br s, 1H, NH), 7.28 (t, J = 8 Hz, 
1H), 7.00 (dd, J = 8.3, 2 Hz, 1H), 6.79 (dt, J = 8, 2 Hz, 2H), 6.75 (m, 2H), 6.52 (s, 2H), 6.51 (d, J = 12 
Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.88 (s, 3H), 3.80 (s, 6H), 3.69 (s, 6H); 13C NMR (C) 160.4, 152.9 (x 
2), 151.6*, 151.2*, 146.9, 137.2, 132.7, 130.3, 126.8, (CH) 129.6, 129.5, 129.2, 123.9, 119.3*, 113.8, 
111.5, 109.6, 107.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 55.3 (starred signals are low and broad); 
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IR νmax (cm-1) 3421 (N−H), 1751 (C=O); HR ESMS m/z 488.1683 [M+Na]+. Calc. for C26H27NNaO7, 
488.1685. 
4-Methoxyphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (13): off-white solid, 
m. p. 136-138ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.50 (br s, 1H, NH), 7.09 (apparent d, 
J ~ 9 Hz, 2H), 6.99 (dd, J = 8.5, 2 Hz, 1H), 6.89 (apparent d, J ~ 9 Hz, 2H), 6.75 (d, J = 8.5 Hz, 1H), 
6.52 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.44 (d, J = 12 Hz, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H), 
3.70 (s, 6H); 13C NMR (C) 157.1, 152.8 (x 2), 151.8*, 146.8, 144.1, 137.2, 132.7, 130.3, 126.9, (CH) 
129.5, 129.2, 123.8, 122.4 (x 2), 119.2*, 114.3 (x 2), 109.6, 106.1 (x 2), (CH3) 60.8, 55.8 (x 3), 55.5 
(starred signals are low and broad); IR νmax (cm-1) 3419 (N−H), 1748 (C=O); HR ESMS m/z 488.1686 
[M+Na]+. Calc. for C26H27NNaO7, 488.1685. 
o-Tolyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (14): off-white solid, m. p. 146-
148ºC; 1H NMR (500 MHz, CDCl3) δ 8.12 (br s, 1H), 7.55 (br s, 1H, NH), 7.25-7.20 (m, 2H), 7.16 
(apparent t, J ≈ 7.5 Hz, 1H), 7.10 (d, J = 7.5 Hz, 1H), 7.01 (dd, J = 8.5, 1.5 Hz, 1H), 6.76 (d, J = 8.5 
Hz, 1H), 6.52 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.44 (d, J = 12 Hz, 1H), 3.91 (s, 3H), 3.79 (s, 3H), 3.70 
(s, 6H), 2.27 (s, 3H); 13C NMR (C) 152.9 (x 2), 151.2*, 149.1, 146.8, 137.2, 132.7, 130.7, 130.3, 127.0, 
(CH) 131.1, 129.6, 129.2, 126.8, 125.9, 123.9, 122.2, 119.2*, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 
55.8, 16.1 (starred signals are low and broad); IR νmax (cm-1) 3424 (N−H), 1750 (C=O); HR ESMS m/z 
472.1727 [M+Na]+. Calc. for C26H27NNaO6, 472.1736. 
m-Tolyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (15): yellowish solid, m. p. 
113-115ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.50 (br s, 1H, NH), 7.28 (apparent t, J ≈ 7.5 
Hz, 1H), 7.10-7.00 (m, 4H), 6.76 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.51 (d, J ≈ 12 Hz, 1H), 6.45 (d, J = 
12 Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.71 (s, 6H), 2.38 (s, 3H); 13C NMR (C) 152.8 (x 2), 151.5*, 
150.5, 146.8*, 139.4, 137.2, 132.7, 130.3, 126.9, (CH) 129.5, 129.2, 129.0, 126.3, 123.8, 122.2, 119.3*, 
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118.5, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 21.2 (starred signals are low and broad); IR νmax 
(cm-1) 3426 (N−H), 1750 (C=O); HR ESMS m/z 472.1738 [M+Na]+. Calc. for C26H27NNaO6, 
472.1736. 
p-Tolyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (16): off-white solid, m. p. 162-
164ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.50 (br s, 1H, NH), 7.18 (apparent d, J = 8 Hz, 
2H), 7.06 (apparent d, J = 8, Hz, 2H), 7.00 (dd, J = 8.5, 2 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 6.52 (s, 
2H), 6.50 (d, J = 12 Hz, 1H), 6.44 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H), 2.36 (s, 
3H); 13C NMR (C) 152.9 (x 2), 151.6*, 148.4, 146.9, 137.2, 135.2, 132.7, 130.3, 127.0, (CH) 129.8 (x 
2), 129.6, 129.2, 123.8, 121.3 (x 2), 119.3*, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 20.8 
(starred signals are low and broad); IR νmax (cm-1) 3425 (N−H), 1750 (C=O); HR ESMS m/z 472.1728 
[M+Na]+. Calc. for C26H27NNaO6, 472.1736. 
2-(Trifluoromethyl)phenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (17): off-
white solid, m. p. 132-134ºC; 1H NMR (500 MHz, CDCl3) δ 8.09 (br s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 
7.60-7.55 (m, 2H), 7.35 (m, 2H), 7.01 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.50 
(d, J = 12 Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.90 (s, 3H), 3.77 (s, 3H), 3.70 (s, 6H); 13C NMR (C) 152.9 
(x 2), 150.4*, 148.0, 147.0, 137.2, 130.3, 126.5, 123.1 (quadruplet with 2JC−F ∼ 31 Hz), 121.9, (CH) 
132.8, 129.4, 129.3, 126.8 (quadruplet with 3JC−F ∼ 4 Hz), 125.7, 124.6, 124.3, 119.2*, 109.7, 106.0 (x 
2), (CH3) 60.8, 55.9 (x 3) (starred signals are low and broad). IR νmax (cm-1) 3425 (N−H), 1762 (C=O); 
HR ESMS m/z 526.1448 [M+Na]+. Calc. for C26H24F3NNaO6, 526.1453.  
3-(Trifluoromethyl)phenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (18): 
viscous oil; 1H NMR (500 MHz, CDCl3) δ 8.06 (br s, 1H), 7.55-7.45 (m, 4H), 7.40 (br s, 1H), 7.02 (dd, 
J = 8.5, 2 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.51 (s, 2H), 6.51 (d, J = 12 Hz, 1H), 6.46 (d, J = 12 Hz, 
1H), 3.91 (s, 3H), 3.80 (s, 3H), 3.70 (s, 6H); 13C NMR (C) 152.9 (x 2), 150.7, 150.6*, 147.0*, 137.2, 
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132.7, 131.8 (center point of quadruplet with 2JC−F ∼ 33 Hz), 130.4, 126.4, 123.5 (center point of 
quadruplet with 1JC−F ∼ 270 Hz), (CH) 129.9, 129.4, 129.3, 125.1, 124.3, 122.2 (quadruplet with 3JC−F ∼ 
4 Hz), 119.3*, 118.8 (quadruplet with 3JC−F ∼ 4 Hz), 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8 
(starred signals are low and broad); IR νmax (cm-1) 3425 (N−H), 1753 (C=O); HR ESMS m/z 526.1452 
[M+Na]+. Calc. for C26H24F3NNaO6, 526.1453. 
4-(Trifluoromethyl)phenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (19): off-
white solid, m. p. 138-141ºC; 1H NMR (500 MHz, CDCl3) δ 8.07 (br s, 1H), 7.66 (apparent d, J = 7.5 
Hz, 2H), 7.55 (br s, 1H, NH), 7.32 (apparent d, J = 7.5 Hz, 2H), 7.03 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 
8.5 Hz, 1H), 6.52 (s, 2H), 6.51 (d, J ≈ 12 Hz, 1H), 6.46 (d, J = 12 Hz, 1H), 3.91 (s, 3H), 3.81 (s, 3H), 
3.71 (s, 6H); 13C NMR (C) 153.2, 152.9 (x 2), 150.5*, 147.0*, 137.3, 132.7, 130.4, 127.7 (center point 
of quadruplet with 2JC−F ∼ 32 Hz), 126.4, 123.8 (center point of quadruplet with 1JC−F ∼ 270 Hz), (CH) 
129.4 (x 2), 126.6 (x 2) (quadruplet with 3JC−F ∼ 4 Hz), 124.3, 121.9 (x 2), 119.4*, 109.7, 106.1 (x 2), 
(CH3) 60.8, 55.9 (x 2), 55.8 (starred signals are low and broad); IR νmax (cm-1) 3426 (N−H), 1751 
(C=O); HR ESMS m/z 526.1448 [M+Na]+. Calc. for C26H24F3NNaO6, 526.1453.  
2,6-Dimethylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (20): off-white 
solid, m. p. 109-111ºC; 1H NMR (500 MHz, CDCl3) δ 8.15 (br s, 1H), 7.60 (br s, 1H, NH), 7.07 (br s, 
3H), 7.00 (dd, J = 8.5, 1.5 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.53 (s, 2H), 6.49 (d, J = 12 Hz, 1H), 6.44 
(d, J = 12 Hz, 1H), 3.91 (s, 3H), 3.78 (s, 3H), 3.70 (s, 6H), 2.23 (s, 6H); 13C NMR (C) 152.9 (x 2), 
150.8*, 147.7, 146.8*, 137.2, 132.7, 130.9 (x 2), 130.3, 127.0, (CH) 129.5, 129.2, 128.5 (x 2), 125.8, 
123.8, 119.0*, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 16.2 (x 2) (starred signals are low and 
broad); IR νmax (cm-1) 3426 (N−H), 1749 (C=O); HR ESMS m/z 486.1891 [M+Na]+. Calc. for 
C27H29NNaO6, 486.1893. 
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3,5-Dimethylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (21): viscous oil; 
1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.50 (br s, 1H, NH), 7.00 (dd, J = 8.5, 1.5 Hz, 1H), 6.88 
(br s, 1H), 6.80 (br s, 2H), 6.75 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.44 (d, J = 
12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H), 2.33 (s, 6H); 13C NMR (C) 152.9 (x 2), 151.6*, 
150.5, 146.8*, 139.2 (x 2), 137.2*, 132.8, 130.4, 127.0, (CH) 129.6, 129.2, 127.3, 123.8, 119.3,* 119.2 
(x 2), 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 21.2 (x 2) (starred signals are low and broad); IR 
νmax (cm-1) 3427 (N−H), 1750 (C=O); HR ESMS m/z 486.1898 [M+Na]+. Calc. for C27H29NNaO6, 
486.1893. 
2,3-Dimethylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (22): yellowish 
solid, m. p. 136-138ºC; 1H NMR (500 MHz, CDCl3) δ 8.13 (br s, 1H), 7.56 (br s, 1H, NH), 7.11 (br t, J 
= 7.6 Hz, 1H), 7.06 (br d, J = 7.6, Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.95 (d, J = 7.6 Hz, 1H), 6.76 (d, J 
= 8.5 Hz, 1H), 6.52 (s, 2H), 6.49 (d, J = 12 Hz, 1H), 6.44 (d, J = 12 Hz, 1H), 3.91 (s, 3H), 3.80 (s, 3H), 
3.70 (s, 6H), 2.32 (s, 3H), 2.16 (s, 3H); 13C NMR (C) 152.9 (x 2), 151.5*, 148.9, 146.8*, 138.4, 137.2, 
132.7, 130.3, 129.3, 127.1, (CH) 129.6, 129.2, 127.4, 126.0, 123.8, 119.7, 119.2*, 109.6, 106.1 (x 2), 
(CH3) 60.8, 55.9 (x 2), 55.8, 20.0, 12.3 (starred signals are low and broad); IR νmax (cm-1) 3424 (N−H), 
1750 (C=O); HR ESMS m/z 486.1889 [M+Na]+. Calc. for C27H29NNaO6, 486.1893. 
3,4-Dimethylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (23): viscous oil; 
1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.50 (br s, 1H, NH), 7.13 (d, J = 8 Hz, 1H), 6.99 (d, J = 
8.5 Hz, 1H), 6.96 (br s, 1H), 6.90 (d, J = 8 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.50 (d, J = 
12 Hz, 1H), 6.44 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H), 2.27 (s, 3H), 2.25 (s, 3H); 
13C NMR (C) 152.9 (x 2), 151.8*, 148.5, 146.8*, 137.7, 137.2, 133.9, 132.8, 130.4, 127.0, (CH) 130.2, 
129.7, 129.2, 123.8, 122.6, 119.3*, 118.7, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 19.8, 19.1 
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(starred signals are low and broad); IR νmax (cm-1) 3427 (N−H), 1750 (C=O); HR ESMS m/z 486.1896 
[M+Na]+. Calc. for C27H29NNaO6, 486.1893. 
3-Chloro-2-methylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (24): off-
white solid, m. p. 130-132ºC; 1H NMR (500 MHz, CDCl3) δ 8.10 (br s, 1H), 7.60 (br s, 1H, NH), 7.27 
(d, J = 8 Hz, 1H), 7.15 (t, J = 8 Hz, 1H), 7.05-7.00 (m, 2H), 6.77 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 6.50 
(d, J = 12 Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.90 (s, 3H), 3.79 (s, 3H), 3.70 (s, 6H), 2.30 (s, 3H); 13C 
NMR (C) 152.9 (x 2), 150.8*, 149.6, 146.8*, 137.2, 135.3, 132.6, 130.3, 129.7, 126.6, (CH) 129.4, 
129.3, 126.7, 126.6, 124.1, 120.8, 119.2*, 109.6, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 13.3 (starred 
signals are low and broad); IR νmax (cm-1) 3424 (N−H), 1751 (C=O); HR ESMS m/z 506.1354 
[M+Na]+. Calc. for C26H26O6NNaCl, 506.1346. 
4-Chloro-3-methylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (25): viscous 
oil; 1H NMR (500 MHz, CDCl3) δ 8.06 (br s, 1H), 7.50 (br s, 1H, NH), 7.33 (d, J = 8.8 Hz, 1H), 7.08 
(s, 1H), 7.01 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.51 (s, 2H), 6.50 
(d, J = 12 Hz, 1H), 6.45 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H), 2.38 (s, 3H); 13C 
NMR (C) 152.9 (x 2), 151.2*, 148.9, 146.9*, 137.3, 137.2*, 132.7, 131.1*, 130.4, 126.7, (CH) 129.6, 
129.5, 129.3, 124.1, 124.0, 120.3, 119.3*, 109.7, 106.1 (x 2), (CH3) 60.8, 55.9 (x 2), 55.8, 20.1 (starred 
signals are low and broad); IR νmax (cm-1) 3424 (N−H), 1751 (C=O); HR ESMS m/z 506.1340 
[M+Na]+. Calc. for C26H26O6NNaCl, 506.1346. 
3-Chloro-4-methylphenyl (Z)-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)carbamate (26): viscous 
oil; 1H NMR (500 MHz, CDCl3) δ 8.06 (br s, 1H), 7.50 (br s, 1H, NH), 7.22 (m, 2H), 7.00 (m, 2H), 
6.75 (d, J = 8.5 Hz, 1H), 6.51 (s, 2H), 6.50 (d, J = 12 Hz, 1H), 6.46 (d, J = 12 Hz, 1H), 3.90 (s, 3H), 
3.81 (s, 3H), 3.70 (s, 6H), 2.37 (s, 3H); 13C NMR (C) 152.9 (x 2), 151.1*, 148.9, 146.9*, 136.3, 134.4, 
133.4, 132.7, 130.4, 126.7, (CH) 131.0, 129.5, 129.3, 124.1, 122.4, 119.9*, 119.4, 109.7, 106.1 (x 2), 
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(CH3) 60.9, 55.9 (x 2), 55.8, 19.4 (starred signals are low and broad); IR νmax (cm-1) 3425 (N−H), 1752 
(C=O); HR ESMS m/z 506.1350 [M+Na]+. Calc. for C26H26O6NNaCl, 506.1346. 
 
5.2. Biological studies. Materials and methods 
5.2.1. Cell culture  
Cell culture media were purchased from Gibco (Grand Island, NY). Fetal bovine serum (FBS) was 
obtained from Harlan-Seralab (Belton, U.K.). Supplements and other chemicals not listed in this 
section were obtained from Sigma Chemical Co. (St. Louis, MO). Plastics for cell culture were 
supplied by Thermo Scientific BioLite. All tested compounds were dissolved in DMSO at a 
concentration of 10 mM and stored at −20°C until use. 
HT-29, MCF-7, HeLa, A549, MDA-MB-231, HL-60 and HEK-293 cell lines were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), 
penicillin (50 μg/mL), streptomycin (50 μg/mL), and amphotericin B (1.25 μg/mL), supplemented with 
10% FBS. HMEC-1 cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM)/Low 
glucose containing glutamine (2 mM), penicillin (50 μg/mL), streptomycin (50 μg/mL), and 
amphotericin B (1.25 μg/mL), supplemented with 10% FBS. For the development of tube formation 
assays in Matrigel, HMEC-1 cells were cultured in EGM-2MV Medium supplemented with EGM-
2MV SingleQuots. 
5.2.2. Cell proliferation assay 
In 96-well plates, 3 × 103 (HeLa, A549, HMEC-1, HEK-293), 5 × 103 (HT-29, MCF-7) or 1 × 104 
(HL-60) cells per well were incubated with serial dilutions of the tested compounds in a total volume of 
100 μL of their respective growth media. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide (MTT; Sigma Chemical Co.) dye reduction assay in 96-well microplates was used, as 
previously described [18]. After 2 days of incubation (37 °C, 5% CO2 in a humid atmosphere), 10 μL 
of MTT (5 mg/mL in phosphate-buffered saline, PBS) was added to each well, and the plate was 
incubated for a further 3 h (37 °C). For adherent cells, the supernatant was discarded and replaced by 
100 µL of DMSO to dissolve formazan crystals. For non-adherent cells (HL-60), plates are 
centrifugated at 800 rpm for 5 min before discarding the supernatant. The absorbance was then read at 
540 nm by spectrophotometry. Three independent experiments were performed, and the IC50 values 
(i.e., concentration half inhibiting cell proliferation) were graphically determined using GraphPad 
Prism 4 software. 
In the case of MDA-MB-231 cells, 1 × 104 cells per well were seeded in 48-well plates in 1 mL of 
growth medium. One day later, 5-fold dilutions of the compounds were added. After 3 days of 
incubation, cells were trypsinized and counted in a Coulter counter (Rega Institute for Medical 
Research, KU Leuven). The IC50 value was determined as the compound concentration required to 
reduce cell proliferation by 50%. 
5.2.3. Tubulin self-assembly assay 
Purified tubulin was used for these measurements. Tubulin polymerization was carried out in a 96 
well-plate. In each well 50 µL of a solution of 25 µM of tubulin in GAB buffer was added to 50 µL of 
27.5 µM solution of the corresponding compounds in GAB buffer (20 mM sodium phosphate, 10 mM 
MgCl2, 1 mM EGTA, 30% glycerol) and 0.1 mM GTP at pH = 6.5. Then, the plate was incubated at 
37ºC in Multiskan® and absorbance at 340 nM was registered every 30 seconds during 2 hours. 
5.2.4. EBI assay 
MDA-MB-231 cells were seeded in 6-well plates at 5 × 105 cells per well. After 48 h, compounds 
were added to the cells for 16 h before adding EBI (N, N’-ethylene-bis(iodoacetamide)) at 100 μM. 
After 1.5 h, cells were harvested and cell extracts were prepared for Western Blot analysis. Thirty μg of 
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proteins were subjected to gel electrophoresis using 0.1% SDS (85% purity) and 10% polyacrylamide 
gels. After electrophoresis, proteins were transferred to pretreated Hybond-P polyvinylidene difluoride 
(PVDF) membranes, which were incubated overnight at 4ºC in blocking buffer (2.5% non-fat dry milk 
in PBS containing 0.1% Tween) and subsequently for 1 h at rt in blocking buffer primary antibody 
raised against β-tubulin. After washing, membranes were incubated with the corresponding HRP-
conjugated secondary antibody in blocking buffer for 30 min at rt. Next, membranes were washed 
extensively and immunoreactive proteins were detected by chemiluminiscence (ECLplus, Bio-Rad). 
5.2.5. Cell cycle analysis 
Progression of the cell cycle was analysed by means of flow cytometry with propidium iodide. After 
incubation with compounds for 24 h, A549 cells were fixed, treated with RNase and stained with 
propidium iodide following instructions of BD CycletestTM DNA Kit. Analysis was performed with a 
BD AccuriTM C6 flow cytometer. 
5.2.6. Immunofluorescence assay 
Immunofluorescent analysis of the microtubule network was performed on the A-549 cell line. In 
this assay, 1,5x105 cells were plated on a coverglass and incubated with the different concentrations of 
selected compounds for 16 h. Cells were then washed with PEMP, permeabilized with PEM-Triton X-
100 0.5% for 90 seconds at room temperature and fixed in 3.7% formaldehyde (in PEM pH 7.4) for 30 
min at rt. Direct immunostaining was carried out for 2.5 h at 37°C in darkness with primary FITC-
conjugated anti-α-tubulin antibody (dilution 1:400 in PBS-BSA 1% from a 1 mg/mL solution; 
monoclonal antibody, clone DM1A, Sigma-Aldrich). Next, cells were washed with PBS and incubated 
for 30 min at room temperature in darkness with Hoechst 2 mM in water. Then, cells were washed in 
PBS and coverglasses were mounted with 10 μL of Glycine/Glycerol buffer. The cytoskeleton was 
imaged by a confocal laser scanning microscope (CLSM) Leica SP5 with a Leica inverted microscope, 
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equipped with a Plan-Apochromat 63× oil immersion objective (NA=1.4). Each image was recorded 
with the CLSM’s spectral mode selecting specific domains of the emission spectrum. The FITC 
fluorophore was excited at 488 nm with an argon laser and its fluorescence emission was collected 
between 496 nm and 535 nm. 
5.2.7. Apoptosis assay 
Apoptosis was determined by quantifying FITC-Annexin V translocation by means of flow 
cytometry. A549 cells were incubated with compounds for 24 h and then stained following instructions 
of BD Apoptosis DetectionTM Kit. Analysis was performed with a BD AccuriTM C6 flow cytometer. 
5.2.8. Tube destruction assay 
Wells of a 96-well μ-plate for angiogenesis were coated with 12 μL of Matrigel (10 mg/mL, BD 
Biosciences) at 4ºC. After gelatinization at 37ºC for 30 min, HMEC-1 cells were seeded at 2 x 104 
cells/well in 35 μL of culture medium on top of the Matrigel. After 20 h of incubation at 37ºC, when 
tube-like structures were detectable, compounds were added at different concentrations. Next, 4 h later, 
tube destruction was evaluated by giving a score from 0 to 3 (3: intact tubular network as seen in the 
control, 2: missing connections and/or dead ends; 1: many separate small tubes that are not connected; 
0: no tubes). 
5.2.9. Proteins and ligands 
Calf brain tubulin was purified as described previously [19]. 
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List of captions 
Figure 1.  
Figure 2. 
Scheme 1. Reagents and conditions: Method a: ArOCOCl, pyridine, THF, 0ºC 30 min then rt 1 h. Method b: (i) 
Triphosgene, Et3N, THF, rt, 10 min; (ii) ArOH, THF, 45ºC, 1 h. 
Figure 3. Structure of the carbamates investigated in this study.. 
Table 1. IC50 values (nM) for CA-4, AmCA-4 and derivatives 1-26.a 
Table 2. Critical Concentration (CrC) for the assembly of purified tubulin in GAB in the presence of 
CA-4, AmCA-4 or the carbamates. 
Figure 4. Effects of CA-4, AmCA-4 and carbamates on the in vitro tubulin polymerization. 
Figure 5. Effects of colchicine and carbamates at the colchicine-binding site of tubulin. 
Table 3. Cell cycle distribution (%). 
Figure 6. Effects of AmCA-4 and some selected carbamates on the microtubule network. A549 cells 
were treated for 16 hours and processed for immunofluorescence microscopy: (A) DMSO, (B) 230 nM 
AmCA-4, (C) 150 nM compound 1, (D) 300 nM compound 3, (E) 260 nM compound 5, (F) 200 nM 
compound 6, (G) 220 nM compound 17 and (H) 260 nM compound 18. 
Figure 7. Apoptotic effect of AmCA-4 and carbamates. Data are the average (±SD) of three 
experiments. 
Figure 8. Tube destruction effect of selected carbamates. All the compounds were tested at 3 µM, 1 
µM, 300 nM, 30 nM, 10 nM and 3 nM 










































1 (R1, R2=H, method a , 89%)
2 (R1=2-F, R2=H, method b, 73%)
3 (R1=3-F, R2=H, method b, 33%)
4 (R1=4-F, R2=H, method a , 64%)
5 (R1=2-Cl, R2=H, method b, 35%)
6 (R1=3-Cl, R2=H, method b, 33%)
7 (R1=4-Cl, R2=H, method a , 62%)
8 (R1=2-Br, R2=H, method b, 36%)
9 (R1=3-Br, R2=H, method b, 58%)
10 (R1=4-Br, R2=H, method b, 61%)
11 (R1=2-OMe, R2=H, method b, 41%)
12 (R1=3-OMe, R2=H, method b, 91%)
13 (R1=4-OMe, R2=H, method b, 73%)
14 (R1=2-Me, R2=H, method b , 27%)
15 (R1=3-Me, R2=H, method b, 45%)
16 (R1=4-Me, , R2=H, method b, 49%)
17 (R1=2-CF3, R
2=H, method b , 65%)
18 (R1=3-CF3, R
2=H, method b, 50%)
19 (R1=4-CF3, R
2=H, method b, 75%)
20 (R1=2-Me, R2=6-Me, method b, 24%)
21 (R1=3-Me, R2=5-Me, method b, 18%)
22 (R1=2-Me, R2=3-Me, method b, 28%)
23 (R1=3-Me, R2=4-Me, method b, 27%)
24 (R1=2-Me, R2=3-Cl, method b, 55%)
25 (R1=3-Me, R2=4-Cl, method b, 31%)









Comp. HT-29 MCF-7 HeLa A549 HL-60 HMEC-1 HEK-293 
CA-4 4200 ± 500 1000 ± 200 2100 ± 600 130 ± 20  4000 ± 1000 3400 ± 400 25000 ± 300 
AmCA-4 22.0 ± 0.7 8.0 ± 0.9 2.6 ± 0.5 117 ± 7 4.5 ± 0.9 12 ± 6 7.1 ± 1.0 
1 2.9 ± 0.5 9.8 ± 0.1 4.8 ± 0.2 77 ± 12 4 ± 2 12 ± 5 3.3 ± 0.2 
2 110 ± 30 62 ± 2 17 ± 2 320 ± 190 4 ± 2 180 ± 20 65 ± 4 
3 10.6 ± 0.5 7.0 ± 0.6 2.7 ± 1.3 150 ± 40 60 ± 20 20 ± 2 13.2 ± 0.2 
4 60 ± 20 95.4 ± 1.3 60 ± 20 400 ± 200 50 ± 30 65 ± 13 185 ± 2 
5 17.8 ± 0.7 10.1 ± 0.8 5 ± 2 130 ± 40 3.7 ± 0.7 50 ± 30 41 ± 2 
6 9.2 ± 1.3 4.4 ± 0.6 4.79 ± 0.03 100 ± 20 13.5 ± 1.6 9 ± 6 14.5 ± 0.4 
7 31 ± 14 82 ± 13 24 ± 3 800 ± 200 770 ± 170 76 ± 13 142 ± 9 
8 7.5 ± 0.6 18.9 ± 0.9 2.6±1.0 180 ± 50 3 ± 2 22 ± 7 8 ± 5 
9 11.3 ± 0.7 5.9 ± 0.3 2.6±0.5 160 ± 30 5.6 ± 0.6 12 ± 4 16 ± 2 
10 3.5 ± 0.2 0.75 ± 0.05 1.2±0.2 150 ± 30 5 ± 3 7 ± 4 19 ± 7 
11 290 ± 100 230 ± 180 348 ± 13 3000 ± 1100 350 ± 190 400 ± 15 160 ± 40 
12 4.8 ± 0.5 7.18 ± 0.07 3.4 ± 0.4 160 ± 40 4.9 ± 0.5 5 ± 2 8.1 ± 0.2 
13 350 ± 20 230 ± 30 200 ± 40 550 ± 120 50 ± 6 120 ± 50 130 ± 40 
14 160 ± 70 380 ± 50 50 ± 30 460 ± 110 222 ± 7 55 ± 6 60 ± 20 
15 46 ± 3 25 ± 9 23 ± 13 390 ± 180 67 ± 2 50 ± 20 40 ± 20 
16 270 ± 80 200 ± 60 370 ± 160 1500 ± 300 52 ± 2 160 ± 40 144 ± 10 
17 16 ± 7 44 ± 2 15 ± 4 110 ± 40 6.7 ± 0.6 19 ± 5 4.1 ± 1.0 
18 13 ± 3 56 ± 9 40 ± 8 130 ± 60 4 ± 2 16 ± 5 42.2 ± 0.9 
19 27.6 ± 0.6 9.2 ± 0.3 21 ± 8 270 ± 70 40 ± 30 30 ± 8 57 ± 22 
20 600 ± 200 440 ± 14 320 ± 120 3900 ± 1200 470 ± 70 380 ± 140 490 ± 80 
21 260 ± 140 210 ± 20 130 ± 16 1540 ± 80 620 ± 90 180 ± 7 150 ± 80 
22 175 ± 4 16 ± 3 40 ± 20 900 ± 200 59 ± 13 140 ± 40 80 ± 30 
23 130 ± 20 170 ± 30 21 ± 6 1300 ± 600 69 ± 11 130 ± 50 97 ± 9 
24 47 ± 2 39 ± 3 23 ± 12 140 ± 30 70 ± 30 20 ± 2 14 ± 2 
25 11.4 ± 0.3 8.1 ± 0.9 3.3 ± 0.5 140 ± 30 0.4 ± 0.2 7 ± 1 8.4 ± 0.6 
26 23 ± 2 6.1 ± 0.8 3.7 ± 0.3 90 ± 20 1.8 ± 0.6 6 ± 2 7.0 ± 0.8 
aIC50 values are expressed as the compound concentration (nM) that inhibits the cell growth by 50%. Data are the 




Compound CrC (µM) Compound CrC (µM) 
Control   8 ± 1 13 23 ± 2 
CA-4 22 ± 1 14 22 ± 3 
AmCA-4 23 ± 2 15 20 ± 3 
1 20 ± 2 16 25 ± 2 
2 18 ± 3 17 23 ± 2 
3 24 ± 4 18 14 ± 2 
4 22 ± 2 19 20 ± 3 
5 21 ± 3 20 17 ± 3 
6 23 ± 2 21 24 ± 2 
7 24 ± 2 22 25 ± 2 
8 22 ± 2 23 21 ± 2 
9 25 ± 3 24 23 ± 1 
10 23 ± 2 25 24 ± 3 
11 16 ± 1 26 24 ± 3 
12 20 ± 2   








































Comp. Conc (nM) SubG0 G0/G1 S G2/M 
Control - 6.6 ± 0.1 66 ± 1 16 ± 1 11 ± 1  
CA-4 50 15 ± 1 21 ± 2 22 ± 1 43 ± 1 
AmCA-4 60 14 ± 1 21 ± 1 24 ± 1 41 ± 2 
1 40 20 ± 3 21 ± 1 15 ± 1 44 ± 3 
2 160 17 ± 1 31 ± 3 13 ± 1 39 ± 2 
3 75 19 ± 1 29 ± 1 10 ± 1 43 ± 2 
4 200  21 ± 1 26 ± 5 19 ± 1 34 ± 1 
5 65 16 ± 1 29 ± 2 12 ± 2 43 ± 3 
6 50 16 ± 2 30 ± 1 10 ± 1 44 ± 2 
7 400 20 ± 1 21 ± 1 18 ± 1 41 ± 1 
8 90 17 ± 2 29 ± 1 10 ± 1 44 ± 3 
9 80 17 ± 3 30 ± 1 12 ± 1 39 ± 1 
10 75 19 ± 1 32 ± 3 17 ± 1 33 ± 1 
11 1500 17 ± 1 29 ± 4 12 ± 3 43 ± 1 
12 80 17 ± 1 31 ± 1 16 ± 2 36 ± 3 
13 275 14 ± 1 25 ± 1 14 ± 1 46 ± 2 
14 230 16 ± 1 31 ± 2 13 ± 2 40 ± 1 
15 200 22 ± 3 26 ± 2 16 ± 3 36 ± 1 
16 750 27 ± 5 24 ± 1 16 ± 2 32 ± 3 
17 55 20 ± 2 21 ± 2 15 ± 1 44 ± 5 
18 65 16 ± 3 28 ± 1 15 ± 1 41 ± 1 
19 135 26 ± 1 22 ± 1 14 ± 1 39 ± 2 
20 2000 23 ± 2 25 ± 2 17 ± 1 35 ± 1 
21 750 22 ± 3 24 ± 3 16 ± 1 38 ± 1 
22 450 12 ± 1 24 ± 1 22 ± 3 42 ± 2 
23 650 17 ± 1 24 ± 1 19 ± 1 41 ± 1 
24 70 20 ± 1 24 ± 1 18 ± 2 39 ± 1 
25 70 18 ± 1 24 ± 1 22 ± 9 36 ± 8 
26 45 29 ± 4 21 ± 1 14 ± 1 36 ± 3 
a
 Data are the average (±SD) of three experiments. 
 
 45
  
 
Figure 6. 
 46
 
Figure 7. 
 47
 
Figure 8. 
 
 48
 
Figure 9. 
 
 
